Patricia Inácio, PhD, science writer —

Patients with chronic obstructive pulmonary disease (COPD) carry much higher levels of glucose in their airways, increasing the growth of bacteria and consequently the risk of infections, according to researchers from Imperial College London. Their study, “Role of airway glucose in bacterial infections in patients with chronic obstructive…

GlaxoSmithKline (GSK) and Innoviva recently presented positive results of a study showing that Anoro Ellipta is more effective than Stiolto Respimat in symptomatic patients with chronic obstructive pulmonary disease (COPD). The results were presented at the 2017 CHEST Annual Meeting of the American College of Chest Physicians in Toronto, Canada,…

Stem cells offer protective effects for damaged lung cells exposed to cigarette smoking by alleviating oxidative stress in mitochondria, a study shows. These results were also observed in mice and suggest a potential new therapeutic strategy for oxidative stress-dependent lung diseases, such as chronic obstructive pulmonary disease (COPD). The study…

INOpulse as a therapy for pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) showed promising results in a Phase 2 clinical trial, Bellerophon Therapeutics, the clinical-stage company developing the INOpulse program, announced. INOpulse is a portable nitric oxide delivery system being developed for the treatment of PH-COPD. Nitric oxide…

Propeller Health and GlaxoSmithKline (GSK) will extend their collaboration in which patients with chronic obstructive pulmonary disease (COPD) and asthma use Propeller’s clip-on sensor and software platform with GSK’s Ellipta Inhaler to help them manage their illnesses. The new extended partnership, first announced in 2015, will allow Propeller and GSK to…

Bronchiectasis is increasingly recognized in patients with chronic obstructive pulmonary disease (COPD) who have worsening symptoms, including exacerbations and higher risk for pneumonia. Researchers presented their study, “Bronchiectasis in COPD: An Irrelevant Imaging Finding or a Clinically Important Phenotype?”  at the 2016 CHEST Annual Meeting in Los…

A component of red wine and grapes, resveratrol, was seen to halt the pathogen-induced inflammation common in respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma. The study, “Resveratrol suppresses NTHi-induced inflammation via up-regulation of the negative regulator MyD88 short,” was published in the online…

Chronic obstructive pulmonary disease (COPD) is currently the third leading cause of death in the United States. But while significant scientific progress is being made, COPD patients face serious challenges when it comes to treatment access, particularly because  treatments costs are high and hospitals have not yet reached recommended standards for COPD care. The startling opinions,…

During this year’s Respiratory Effectiveness Group (REG) Summit (2016 REG Summit), researchers from around the globe highlighted the urgent need for more research into current therapies for chronic obstructive pulmonary disease (COPD). According to a news release, this concern is in line with the announcement by members of the…

Researchers discovered that patients with chronic obstructive pulmonary disease (COPD) show increased levels of a protein that inhibits the immune system response against several pathogens, thereby increasing their vulnerability to infections. The study, “Osteopontin That Is Elevated in the Airways during COPD Impairs the Antibacterial Activity of Common Innate…